Thrombin Time (TT) analysis is a core coagulation assay that measures the time required for platelet-poor plasma to form a fibrin clot after the addition of a standardized thrombin reagent. Because it directly evaluates the final step of the coagulation cascade, the conversion of fibrinogen to fibrin, TT testing is widely used to detect heparin contamination, diagnose fibrinogen disorders, and support the evaluation of disseminated intravascular coagulation and anticoagulant therapy.
Technical Overview
Thrombin Time (TT) is defined as the interval between the addition of a known quantity of thrombin to citrated platelet-poor plasma and the formation of a visible fibrin clot. Unlike prothrombin time (PT) and activated partial thromboplastin time (APTT), which assess upstream coagulation pathways, the TT assay bypasses the enzymatic cascade entirely and interrogates only the terminal reaction: the proteolytic cleavage of fibrinopeptides A and B from fibrinogen by thrombin, followed by fibrin monomer polymerization and clot formation.
Consequently, TT is exclusively sensitive to factors that influence this final step, including:
- The concentration and functional quality of fibrinogen in the plasma sample
- The presence of thrombin inhibitors such as heparin, hirudin, argatroban, or dabigatran
- Elevated levels of fibrin and fibrinogen degradation products (FDP), including D-dimer
- Paraproteins and abnormal proteins that interfere with fibrin polymerization
Typical adult reference intervals fall within approximately 14 to 21 seconds, although each laboratory must establish or verify its own interval based on the specific thrombin reagent, instrument, and population served. A prolonged TT with otherwise normal PT and APTT is a classic analytical pattern pointing to heparin contamination, dysfibrinogenemia, or direct thrombin inhibitor therapy. Testing procedures are typically governed by Clinical and Laboratory Standards Institute (CLSI) guidance on coagulation specimen handling, with laboratory quality systems conforming to ISO 15189 medical laboratory accreditation requirements.
Testing Samples
Citrated Platelet-Poor Plasma
The standard specimen is venous blood collected into evacuated tubes containing 3.2% (0.109 mol/L) trisodium citrate anticoagulant at a strict 9:1 blood-to-anticoagulant ratio. Tubes must be filled to at least 90% of their nominal volume, as under-filling causes excess citrate concentration and artifactual prolongation of clotting times. Samples are centrifuged to obtain platelet-poor plasma, generally at approximately 1,500 × g for at least 15 minutes, achieving a residual platelet count below 10 × 10⁹/L to eliminate platelet-derived interference.
Special Population Samples
Neonatal and pediatric specimens may be collected in reduced-volume citrate tubes with appropriately adjusted citrate volumes. Samples from patients receiving unfractionated heparin through indwelling catheters require careful venipuncture technique or line-draw protocols to avoid carryover contamination, and discarding the initial drawn aliquot is recommended.
Quality Control and Calibration Materials
Each analytical run should include normal and abnormal commercial control plasmas at a minimum of two clinically relevant decision levels. Calibration plasmas should be traceable to recognized international reference preparations, such as World Health Organization (WHO) international standards for thrombin and fibrinogen, ensuring metrological comparability across laboratories.
Sample Handling and Stability
- Analyze plasma within 4 hours of collection when stored at room temperature (18–24 °C)
- Do not refrigerate samples prior to testing, as cold activation can alter results
- For delayed testing, freeze platelet-poor plasma at −20 °C or below for up to 2 weeks, or at −70 °C for longer storage
- Reject specimens showing significant hemolysis, clots, or incorrect anticoagulant ratios
Testing Items
The thrombin time analytical panel encompasses several related measurands and interpretive studies:
- Thrombin Time (TT): the primary measurand, reported in seconds with the laboratory reference interval
- Reptilase Time: an ancillary assay using batroxobin, a thrombin-like enzyme insensitive to heparin, used to differentiate heparin effects from fibrinogen abnormalities
- Heparin Neutralization Studies: repeat TT performed after adding protamine sulfate, polybrene, or toluidine blue to confirm heparin as the cause of prolongation
- Functional Fibrinogen (Clauss Method): quantitative fibrinogen determination performed in parallel to distinguish hypofibrinogenemia from qualitative fibrinogen defects
- Dilution Studies: mixing patient plasma with normal pooled plasma to distinguish factor depletion from inhibitory substances
Testing Methods
Optical Clot Detection
Automated coagulation analyzers monitor the change in optical density or scattered light as fibrin strands form. Optical systems offer high throughput and precise endpoint detection but may be affected by icterus, lipemia, or hemolysis, which can interfere with light transmission.
Mechanical Clot Detection
Mechanical methods, including electromagnetic sensor and steel-ball viscosity-based systems, detect the physical resistance change as the clot forms. These methods are inherently resistant to optical interference from bilirubin, lipids, or hemoglobin and are recommended for turbid or discolored specimens.
Reagent and Analyzer Considerations
- Thrombin reagents are typically of bovine or human origin, supplied lyophilized, and reconstituted under strictly controlled conditions according to manufacturer instructions
- Incubation temperature must be maintained at 37 °C, as clotting kinetics are highly temperature-dependent
- Calibration verification and two-level quality control should be performed at defined intervals, with results tracked on Levey-Jennings charts and evaluated using Westgard multirules
- Repeatability coefficients of variation below 5% are generally expected for clinical TT measurement
Method Validation and Compliance
Accredited third-party laboratories and hospital hemostasis laboratories validate TT methods in accordance with ISO 15189 and applicable national standards, covering precision, accuracy, reference interval verification, linearity, and inter-method comparability. Manufacturers of in vitro diagnostic reagents operate under ISO 13485 quality management systems.
Applications
Clinical Diagnostics
- Detection of heparin contamination in specimens, particularly from indwelling catheter draws
- Monitoring of unfractionated heparin therapy and direct thrombin inhibitor exposure, including dabigatran, which profoundly prolongs TT even at therapeutic concentrations
- Diagnosis of hypofibrinogenemia, afibrinogenemia, and dysfibrinogenemia, whether congenital or acquired
- Support for disseminated intravascular coagulation (DIC) scoring when elevated FDP impairs fibrin polymerization
- Assessment of hepatic synthetic failure in advanced liver disease
- Monitoring of thrombolytic therapy, where successful lysis generates FDP that prolong TT
Pharmaceutical and Biopharmaceutical Testing
- Potency and identity testing of thrombin-active pharmaceutical ingredients and topical thrombin hemostatic products
- Quality control of fibrin sealant and tissue adhesive manufacturing
- Pharmacodynamic evaluation of direct thrombin inhibitor drug candidates during preclinical and clinical development
Research Applications
- Hemostasis and thrombosis research, including anticoagulant mechanism studies
- Snake venom enzyme characterization, where thrombin-like enzymes are compared with reptilase-type activity
- Development and verification of novel coagulation reagents and point-of-care systems
FAQ
What is the normal reference range for thrombin time?
Most laboratories report an adult reference interval of approximately 14 to 21 seconds. Because thrombin reagent concentrations and detection methods differ between platforms, each laboratory must establish and periodically verify its own interval.
Why might TT be prolonged while PT and APTT are normal?
This pattern strongly suggests heparin contamination, direct oral anticoagulant therapy with thrombin inhibitors, dysfibrinogenemia, or elevated FDP. Since the upstream cascade is intact, PT and APTT remain unaffected while the final fibrin-forming reaction is impaired.
How does the reptilase time assist interpretation?
Batroxobin, the enzyme used in the reptilase time assay, clots fibrinogen independently of heparin. A prolonged TT with a normal reptilase time indicates heparin or direct thrombin inhibitor presence, whereas prolongation of both assays points to a fibrinogen quantity or quality defect.
Can thrombin time be used to quantify fibrinogen?
No. TT is a screening test sensitive to fibrinogen function but is not quantitative. The Clauss method, which uses high-concentration thrombin under diluted plasma conditions, is the standard quantitative functional fibrinogen assay and should be performed alongside TT when fibrinogen disorders are suspected.
Does dabigatran affect thrombin time?
Yes, TT is exquisitely sensitive to dabigatran and can remain prolonged even at low plasma concentrations. A normal TT effectively excludes clinically significant dabigatran exposure, which makes TT a useful qualitative exclusion tool for this anticoagulant.
Are there interferences laboratory staff should watch for?
Yes. Hemolysis, icterus, lipemia, under-filled citrate tubes, residual platelets in plasma, and paraproteinemias can all distort results. Mechanical clot detection systems and strict adherence to pre-analytical protocols mitigate most of these risks.
